EGFR and non-small cell lung carcinoma: Mechanistically, EGFR inhibition triggered a type I interferon response via activation of the RIG-I/TBK1/IRF3 axis, and inhibition of interferon signaling enhanced EGFR TKI sensitivity in EGFR-mutant NSCLC.